{"groups":[{"description":"Cytarabine 1.5 g/m\\^2 and Idarubicin 12 mg/m\\^2 intravenous (IV) continuously on days 1-3 (or 1-4), with Oral Tipifarnib 200/300 twice daily on days 1-21, repeats every 21 days.","id":"FG000","title":"Idarubicin, Cytarabine + Tipifarnib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"95"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"95"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant enrolled was excluded from the study.","recruitmentDetails":"Recruitment Period: 9/16/2004 to 9/22/2006. All patients registered at The University of Texas M.D. Anderson Cancer Center."}